Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.
about
Oritavancin disrupts membrane integrity of Staphylococcus aureus and vancomycin-resistant enterococci to effect rapid bacterial killingHost-guest chemistry of the peptidoglycanStructural variations of the cell wall precursor lipid II and their influence on binding and activity of the lipoglycopeptide antibiotic oritavancin.Comparison of the efficacy and safety of oritavancin front-loaded dosing regimens to daily dosing: an analysis of the SIMPLIFI trial.Probing the biology of natural products: molecular editing by diverted total synthesis.Current strategies for the treatment of complicated intraabdominal infections.Renaissance of antibiotics against difficult infections: Focus on oritavancin and new ketolides and quinolones.Oritavancin, a single-dose, complete regimen, for the treatment of acute bacterial skin and skin structure infections.Oritavancin: a review in acute bacterial skin and skin structure infections.Dalbavancin and Oritavancin: An Innovative Approach to the Treatment of Gram-Positive Infections.New Found Hope for Antibiotic Discovery: Lipid II Inhibitors.Prolonged Use of Oritavancin for Vancomycin-Resistant Enterococcus faecium Prosthetic Valve Endocarditis.Oritavancin Pharmacokinetics and Bone Penetration in Rabbits.Antistaphylococcal activity of oritavancin and its synergistic effect in combination with other antimicrobial agents.Pharmacodynamics of a simulated single 1,200-milligram dose of oritavancin in an in vitro pharmacokinetic/pharmacodynamic model of methicillin-resistant staphylococcus aureus infection.Oritavancin (Orbactiv): A New-Generation Lipoglycopeptide for the Treatment Of Acute Bacterial Skin and Skin Structure Infections.
P2860
Q24606291-DF4B3340-CD05-4158-8EA0-A53B54E93DDBQ34013593-18594EF3-817C-418A-A54C-CAEDD4547476Q34448260-5B502A66-F521-43B9-82C2-9321AD8A7B77Q35065786-01777C58-9FC3-4DC6-AF2E-085F0F17B544Q37809500-AFB60D39-3D82-4D49-8323-395FF8D9F12DQ38123247-FC92CE32-B08A-489F-8BBB-F662DC8D3AADQ38233471-E3A08042-26AB-4970-B663-32C34637C67AQ38347765-03E5D0AC-7FCA-40DF-8F98-127E02099AB0Q38606618-E00E189F-4C05-4323-BBC2-BFD479F9C89EQ38615330-2CBB481D-71F2-4117-AF42-B8FFB208419BQ38889355-AD931B22-62F5-444A-BD25-79ACBEB036FFQ40201824-504F685C-A003-4D8D-AC3E-BB8EFA7573C9Q41073732-5CA785B9-A3B4-4309-9C11-96F448D55A1EQ41810303-78D10DEA-D052-4EAF-A22C-1B0306113133Q42530056-A2A02DE4-15E2-4767-8746-C970B72A6691Q52680606-EDBB285D-D06A-42B8-98FA-0B5BF0C6131F
P2860
Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
Comparative in vitro activity ...... am-positive clinical isolates.
@en
Comparative in vitro activity ...... am-positive clinical isolates.
@nl
type
label
Comparative in vitro activity ...... am-positive clinical isolates.
@en
Comparative in vitro activity ...... am-positive clinical isolates.
@nl
prefLabel
Comparative in vitro activity ...... am-positive clinical isolates.
@en
Comparative in vitro activity ...... am-positive clinical isolates.
@nl
P2093
P2860
P356
P1476
Comparative in vitro activity ...... ram-positive clinical isolates
@en
P2093
Chris M Pillar
Daniel F Sahm
Deborah C Draghi
Francis F Arhin
Thomas R Parr
P2860
P304
P356
10.1128/AAC.00952-09
P407
P50
P577
2009-09-08T00:00:00Z